杨贵妃传媒視頻

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 杨贵妃传媒視頻 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

WHAT'S NEW

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Jul 28 2020

Full Issue

Vaccine Distribution Snafus Predicted

The U.S. is unprepared to distribute a COVID vaccine, a Democratic think tank says, because of potential shortages of vaccine-brewing equipment, cold storage and raw materials. It predicts major bottlenecks.

A Democratic group warned Tuesday that the U.S. is fundamentally unprepared to manufacture and distribute hundreds of millions of Covid-19 vaccine doses when one becomes available, urging Congress to step up preparedness efforts and spend $40 billion to quickly increase manufacturing and distribution capacity. In a 20-page report published by the Center for American Progress, two leading Democratic health policy figures called the current vaccine manufacturing setup 鈥渉aphazard.鈥 (Facher, 7/28)

Whenever a vaccine for the coronavirus becomes available, one thing is virtually certain: There won鈥檛 be enough to go around. That means there will be rationing. Someone will have to decide which of the world鈥檚 7.8 billion people gets first crack at returning to a more normal life. Infectious disease experts and medical ethicists say this exceptionally complex decision must weigh not only who is most at risk from the virus and who is most likely to spread it, but also who is most important for maintaining the medical and financial health of a nation as well as its safety. (Burling, 7/28)

In business news 鈥

On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. Vaxart鈥檚 shares soared. Company insiders, who weeks earlier had received stock options worth a few million dollars, saw the value of those awards increase sixfold. And a hedge fund that partly controlled the company walked away with more than $200 million in instant profits. (Gelles and Drucker, 7/25)

As scientists begin to clear a path to a potential coronavirus vaccine, researchers and advocates are increasingly sounding the alarm over what they see as a looming threat: Facebook鈥檚 apparent inability to police dangerous falsehoods about vaccines. Since the outset of the pandemic, vaccine-related falsehoods have ballooned on the platform 鈥 and recent research suggests some of those inaccurate posts are gaining traction among people who weren鈥檛 previously opposed to vaccinations. Part of the problem appears to be the way Facebook鈥檚 algorithms capitalize on divisive or extremist content. (Brodwin, 7/28)

The head of the Chinese Center for Disease Control and Prevention says he has been injected with an experimental coronavirus vaccine in an attempt to persuade the public to follow suit when one is approved. 鈥淚鈥檓 going to reveal something undercover: I am injected with one of the vaccines,鈥 Gao Fu said in a webinar Sunday hosted by Alibaba Health, an arm of the Chinese e-commerce giant, and Cell Press, an American publisher of scientific journals. 鈥淚 hope it will work.鈥 (Kang, 7/28)

Also 鈥

If you want to be among the first to get a vaccine for the coronavirus, joining a clinical trial might be your best bet. Vaccine makers are going to need thousands of volunteer testers over the next few months. As with any clinical trial, these new vaccines are experimental, so they may not work. And thousands may also be in the placebo group, so they will have no extra protection against the virus. There鈥檚 also a risk of nasty side effects, but clinical trial participants may feel good about doing something concrete to fight COVID-19. (Burling, 7/27)

Vaccine label changes have made vaccines even safer than they were before, and they remain "remarkably" safe, Israeli-based researchers reported Monday. A review of 58 different changes to labels on vaccines made between 1996 and 2015 has shown very few dangers in vaccination, and changes that were made were mostly to ensure people vulnerable to side effects or allergies were protected, they found. (Thomas, Lin Erdman, Kane and Hetter, 7/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, June 18
  • Wednesday, June 17
  • Tuesday, June 16
  • Monday, June 15
  • Friday, June 12
  • Thursday, June 11
More Morning Briefings
RSS Feeds
  • 杨贵妃传媒視頻
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF